Journal of Cancer Research and Experimental Oncology
Subscribe to JCREO
Full Name*
Email Address*

Article Number - 9EECDCA59698


Vol.8(2), pp. 15-25 , July 2016
DOI: 10.5897/JCREO2015.0124
ISSN: 2141-2243



Review

Immunotherapy against cancer: A comprehensive review



Minda Asfaw Geresu*
  • Minda Asfaw Geresu*
  • School of Agriculture, Animal and Range Sciences Course Team, Madda Walabu University, Bale-Robe, Ethiopia.
  • Google Scholar
Awel Feku Sultan
  • Awel Feku Sultan
  • Bale Zone Livestock and Fisheries Resource Development Office, Bale- Robe, Ethiopia.
  • Google Scholar
Seifudin Kassim Ahmed
  • Seifudin Kassim Ahmed
  • Goba Woreda Livestock and Fisheries Resource and Development Office, Goba, Ethiopia.
  • Google Scholar
Gezahegne Mamo Kassa
  • Gezahegne Mamo Kassa
  • College of Veterinary Medicine and Agriculture, Addis Ababa University, Bishoftu, Ethiopia.
  • Google Scholar







 Received: 19 October 2015  Accepted: 18 May 2016  Published: 31 July 2016

Copyright © 2016 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0


The endeavor of this paper was to review cancer immunotherapy which means the modulating and using of the patient’s own immune system to target the cancer cells rather than using an extrinsic means of therapy. The best way to prevent and remove infections is through the natural 'sterilising' action of the immune response that combines elements of both innate and adaptive immunity to ward off foreign pathogens without medical intervention. The use of immunostimulants, non-specific approach, for cancer therapy is one of the earliest approaches in immunotherapy that aims to enhance the activity of the lymphocytes that are already attacking to the tumour cells but are insufficient to produce a full-powered immune response. In this review, radioimmunotherapy (coupling a radioactive atom to a monoclonal antibody (mAb)), immunotoxins (generated by coupling plant-derived or bacterial toxins to mAbs), antibody-directed enzyme prodrug therapy (an antibody is used as a vector to transfer an enzyme) and immunomodulators were among the discussed approaches to use mAbs as an anti-cancer. A new and promising immunotherapy that is especially highly effective against metastatic melanoma, adoptive cell therapy (ACT), and different cancer vaccines were also reviewed in detail.

Key words: Adoptive cell therapy, cancer immunotherapy, cancer vaccines, immunostimulants, monoclonal antibodies.

Adams GP, Weiner LM (2005). Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23:1147-1157.
Crossref

 

Belardell F (1995). Role of interferons and other cytokines in the regulation of the immune response. APMIS, 103:161-79.
Crossref

 

Belardelli F, Ferrantini M, Proietti E, Kirkwood JM (2002). Interferon-alpha in tumor immunity and immunotherapy. Cytokine and Growth Factor Rev. 13:119-134.
Crossref

 

Bisht M, Bist SS, Dhasmana DC (2010). Biological response modifiers: Current use and future prospects in cancer therapy. Indian J. Cancer, 47(4):443-451.
Crossref

 

Boon T, Coulie PG, Van-den Eynde BJ, van der Bruggen P (2006). Human T cell responses against melanoma. Annu. Rev. Immunol. 24:175-208.
Crossref

 

Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS (2009). Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl. Cancer Inst. 101(19):1348-55.
Crossref

 

Clark JW, Smith JW, Steis RG (1990). Interleukin 2 and lymphokine-activated killer cell therapy: Analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. Cancer Res. 50:7343-7350.

 

Dimberu PM, Leonhardt RM (2011). Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale J. Biol. Med. 84:371-380.

 

Drake CG (2009). Immunotherapy for prostate cancer. J. Clin. Onco. 27:4035-4037.
Crossref

 

Drake CG (2010). Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10:580-593.
Crossref

 

Dudley ME, Wunderlich JR, Yang JC (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23:2346-2357.
Crossref

 

Emeryville CA (2008). Proleukin. Bayer HealthCare Pharmaceuticals, Inc.

 

Fang L, Lonsdorf AS, Hwang ST (2008). Immunotherapy for advanced melanoma. J. Invest. Dermatol. 128:2596-2605.
Crossref

 

Fishman M (2009). A changing world for DCVax: A PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin. Biol. Ther. 9:1565-1575.
Crossref

 

Gelderman KA, Tomlinson S, Ross GD, Gorter A (2004). Complement function in mAb-mediated cancer immunotherapy. Trends Immunol, 25:158-164.
Crossref

 

Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P (2011). Cancer Immunotherapy: Sipuleucel-T and Beyond. Pharmacotherapy 31(8):813-828.
Crossref

 

Hausen HZ (2009). Papillomaviruses in the causation of human cancers: A brief historical account. Virol. 384(2):260-265.
Crossref

 

Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J, Small EJ (2008). Phase 1or 2 dose escalation study of a GM-CSF secreting, allogeneic and cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113:975-984.
Crossref

 

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711-723.
Crossref

 

Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR (2010). Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28: 1099-10105.
Crossref

 

Kipp RT, McNeel DG (2007). Immunotherapy for prostate cancer: Recent progress in clinical trials. Clin. Adv. Hematol. Oncol. 5:465-479.

 

Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ (2008). Next generation of immunotherapy for melanoma. J. Clin. Oncol. 26(20):3445-3455.
Crossref

 

Kreitman RJ, Pastan I (2011). Antibody-fusion proteins: Anti-CD22 recombinant immunotoxin: Moxetumomab pasudotox. Clin. Cancer Res. 17:6398-63405.
Crossref

 

Krieg AM (2002). CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760.
Crossref

 

Krieg AM (2006).Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5:471- 484.
Crossref

 

Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL, Prostvac VF (2009). A vector-based vaccine targeting PSA in prostate cancer. Expert Opin. Investig. Drugs 18:1001-1011.
Crossref

 

Marie LH, Haynes L, Parker C, Iversen P (2012). Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl. Cancer Inst. 104:1-7.

 

Marrari A, Iero M, Pilla L (2007). Vaccination therapy in prostate cancer. Cancer Immunol. Immunother. 56:429-445.
Crossref

 

McNeel DG (2007). Active specific immunotherapy in cancer: Cellular immunotherapies for prostate cancer. Biomed. Pharmacother. 61:315-322.
Crossref

 

Mellman I, Coukos G, Dranoff G (2011). Cancer immunotherapy comes of age. Nature 480(7378):480-489.
Crossref

 

Melton RG, Sherwood RF (1996). Antibody enzyme conjugates for cancer therapy. J. Natl. Cancer Inst. 88(3-4):153-165.
Crossref

 

Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G (1999). Type-I IFN receptor: Structure, function and evolution of a family business. J. Interferon Cytokine Res. 19:1069-1098.
Crossref

 

Pardoll D, Drake C (2012). Immunotherapy earns its spot in the ranks of cancer therapy. J. Exper. Med. 209(2):201-209.
Crossref

 

Pashenkov M, Goëss G, Wagner C, Hörmann M, Jandl T, Moser A, Britten CM, Smolle J, Koller S, Mauch C, Tantcheva-Poor I, Grabbe S, Loquai C, Esser S, Franckson T, Schneeberger A, Haarmann C, Krieg AM, Stingl G, Wagner SN (2006). Phase II trial of a toll-like receptor 9-activating oligonucleotides in patients with metastatic melanoma. J. Clin. Oncol. 24(36):5716-5724.
Crossref

 

Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S (1998). Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58:2489-2499.

 

Reinis M (2008). Biovax ID, a personalized therapeutic vaccine against B-cell lymphomas. Curr. Opin. Mol. Ther. 10:526-534.

 

Rescigno M, Avogadri F, Curigliano G (2007). Challenges and prospects of immunotherapy as cancer treatment. Biochim. Biophys. Acta 1776:108-123.
Crossref

 

Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J (2005). Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP. J. Clin. Onco. 23(35):8968-8977.
Crossref

 

Rosenberg SA, Dudley ME (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opinion Immunol. 21:233-240.
Crossref

 

Rosenberg, SA, Yang JC, Restifo NP (2004). Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10(9):909-915.
Crossref

 

Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008). Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8:299-308.
Crossref

 

Sarid R, Gao SJ (2011). Viruses and human cancer: From detection to causality. Cancer Lett. 305(2):218-227.
Crossref

 

Schuster SJ, Neelapu SS, Guase BL, Muggia FM, Gockerman JP, Sotomayor EM, Winter JN, Flowers CR, Stergiou AM, Kwak LW (2009). Idiotype vaccine therapy (Biovax ID) in follicular lymphoma in first complete remission: phase III clinical trial results. J. Clin. Oncol. 27:18.

 

Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P (2011). gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 365(8):771.
Crossref

 

Sharma P, Wagner K, Wolchok JD, Allison JP (2011). Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nature reviews Cancer 24:(11):805-812.
Crossref

 

Teicher BA, Chari RVJ (2011). Antibody conjugate therapeutics: Challenges and Potential. Clin. Cancer Res. 17:6389-6397.
Crossref

 

Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiani G, Tosti G, Kirkwood JM, Hoos A, Yuh L, Gupta R, Srivastava PK (2008). C-100-21 study group phase III comparison of vitespen: An autologous tumor derived heat shock protein gp96 peptide complex vaccine with physician's choice of treatment for stage IV melanoma. J. Clin. Oncol. 26(6):955-962.
Crossref

 

Todar K (2008). Immune defense against bacterial pathogens: Adaptive or acquired immunity. Todar's Online Textbook of Bacteriology. 

View

 

Van Meir EG, Hadjipanayis CG, Norden AD, Shu Hui-Kuo Wen PY, Olson JJ (2010). Exciting new advances in Neuro-oncology: The avenue to a cure for malignant glioma. CA. Cancer J. Clin. 60(3):166-193.
Crossref

 

Waldmann TA (2003). Immunotherapy: Past, present and future. Nat. Med. 9(3):269-277.
Crossref

 

Waller EK (2007). The Role of Sargramostim (rhGM-CSF) as Immunotherapy. The Oncologist 12(2):22-26.

 

Weiner LM, Surana R, Wang S (2010). Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10:317-327.
Crossref

 

West MA, Wallin RP, Matthews SP, Svensson HG, Zaru R, Ljunggren HG, Prescott AR, Watts C (2004). Enhanced dendritic cell antigen capture via toll-like receptor induced actin remodeling. Sci, 305 (5687):1153-1157.
Crossref

 

Wheeler CJ, Black KL (2009). DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin. Investig. Drugs 18(4):509-519.
Crossref

 

Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, Gupta R, Escudier B (2008). C-100-12 RCC study group an adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open label, randomised phase III trial. Lancet 372:145-154.
Crossref

 

Wrzesinski C, Paulos CM, Gattinoni L (2007). Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells. J. Clin. Invest. 117:492-501.
Crossref

 


APA Geresu, M. A., Sultan, A. F., Ahmed, S. K., & Kassa, G. M. (2016). Immunotherapy against cancer: A comprehensive review. Journal of Cancer Research and Experimental Oncology, 8(2), 15-25.
Chicago Minda Asfaw Geresu, Awel Feku Sultan, Seifudin Kassim Ahmed and Gezahegne Mamo Kassa. "Immunotherapy against cancer: A comprehensive review." Journal of Cancer Research and Experimental Oncology 8, no. 2 (2016): 15-25.
MLA Minda Asfaw Geresu, et al. "Immunotherapy against cancer: A comprehensive review." Journal of Cancer Research and Experimental Oncology 8.2 (2016): 15-25.
   
DOI 10.5897/JCREO2015.0124
URL http://academicjournals.org/journal/JCREO/article-abstract/9EECDCA59698

Subscription Form